Standardising Serialisation: The Deadly World of Falsified and Substandard Medicines

Andrea Charles

Just in the last few months, another dangerous fake drug made its way into the United States, a bogus version of the cancer drug Avastin surfaced in clinics across America in California, Illinois, and Texas. Recent changes to the EU Falsified Medicines Act mean that by 2015 most pharmaceutical companies trading in European countries will have to serialise their products, primarily using 2D data matrix barcodes. In this Pharma IQ exclusive AEI Scholar Roger Bate reveals h...
To continue reading this story get free access